Clinical Trial Update: Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating natural killer cell therapy in combination with Interleukin-2 and the TGF-beta receptor I inhibitor vactosertib for cancer has been s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Colorectal Cancer
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Natural killer cells (natural killer cells)
• Vactosertib (Vactosertib)

Snippet

Sponsor: David Wald | Conditions: Colorectal Cancer, Hematologic Malignancy | Phase 1 | Status: SUSPENDED